Kristie L. Kahl

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

Phase 2 data support further evaluation of datopotamab deruxtecan in patients with non–small cell lung cancer and brain metastases.

The addition of tucidinostat to R-CHOP demonstrated promising safety and efficacy outcomes in patients with previously untreated diffuse large B-cell lymphoma) expressing MYC and BCL-2, according to interim analysis results.

A PFS benefit with adagrasib was observed across all key patient subgroups in the phase 3 KRYSTAL-12 trial.

Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.

Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.

Data from the GETUG-AFU 18 trial support high-dose radiation plus long-term androgen deprivation therapy as a standard of care in high-risk prostate cancer.

Duration of response results with pembrolizumab plus lenvatinib in advanced hepatocellular carcinoma appear to be ‘promising’ in the phase 3 LEAP-002 trial.

Because patients with myeloma are at a high risk for financial hardship, study findings support the use of a financial navigation program to reduce financial toxicities of patients.

Zanubrutinib plus obinutuzumab and venetoclax appears to be well tolerated in patients with TP53-mutated mantle cell lymphoma, says Anita Kumar, MD.

Acalabrutinib on its own or in combination with obinutuzumab increases PFS and ORR in patients with chronic lymphocytic leukemia regardless of mutation status, according to follow-up data from the ELEVATE-TN trial.

Single-agent treatment with odronextamab continued to demonstrate encouraging clinical activity, along with a manageable safety profile, in patients with relapsed/refractory diffuse large B-cell lymphoma.

Treatment with zanubrutinib also appears to improve overall survival compared with ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 3 ALPINE trial.

The use of teclistamab in the real-world phase 2 MajesTEC-1 analysis showed similar safety and efficacy for patients with relapsed/refractory multiple myeloma.

Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for those with hormone receptor–positive breast cancer.

Treatment with nivolumab plus gemcitabine-cisplatin appears to confer rapid and enduring responses in patients with unresectable or metastatic urothelial carcinoma in the phase 3 CheckMate 901 trial.

Subgroup analyses in the phase 3 KEYNOTE-641 trial do not indicate an overall survival improvement with pembrolizumab plus enzalutamide in metastatic castration-resistant prostate cancer.

Shannon N. Westin, MD, MPH, FACOG, presented results showing a progression-free survival response with combination durvalumab plus olaparib in newly diagnosed advanced or recurrent endometrial cancer.

Neoadjuvant nivolumab combination followed by surgery and adjuvant nivolumab show an improvement in event-free survival for patients with previously untreated resectable stage II to IIIB non-small cell lung cancer.

Atezolizumab plus platinum chemotherapy showed significant improvement in progression-free survival for patients with frontline advanced or recurrent endometrial carcinoma.

Event-free survival benefits with pembrolizumab plus chemotherapy in the phase 3 KEYNOTE-522 trial appear to be consistent in triple-negative breast cancer across subgroups based on nodal status, tumor size, and PD-L1 status.

Five-year data from the monarchE trial support adding adjuvant abemaciclib to endocrine therapy for patients with hormone receptor–positive, HER2-negative breast cancer.

Thought leaders from various institutions offered their closing thoughts the 2023 ASCO Annual Meeting.

Thought leaders from various institutions offered their shameless plug the 2023 ASCO Annual Meeting.

Thought leaders from various institutions offered their take on the biggest winner that came out of the 2023 ASCO Annual Meeting.